Axoltis Pharma to participate in ENCALS 2026 and present preliminary SEALS study results

We are pleased to announce Axoltis Pharma’s participation in the ENCALS 2026 Meeting and the TRICALS satellite meeting, which will take place from June 24–26, 2026, at the Palacio Municipal de Congresos in Madrid, Spain.

ENCALS is the leading European scientific meeting dedicated to amyotrophic lateral sclerosis (ALS), bringing together clinicians, researchers, patient organizations and industry representatives from around the world, to share scientific advances and accelerate therapeutic innovation. 

The SEALS study is a Phase 2, multicenter (16 investigation sites – Coordinating Investigator Dr Emilien Bernard – HCL –  France), randomized, double-blind, placebo-controlled clinical trial evaluating NX210c effects in ALS patients. 

The presentation of these preliminary results provides an opportunity to share emerging clinical data with the international ALS research community and contribute to ongoing scientific discussions in the field.

Axoltis Pharma will be represented throughout the congress by members of its clinical team: Dr A. Janus (CMO), S. Marie (Clin.Ops Director) and J.LeDouce (Clin. Project Manager).

We look forward to engaging with the ALS community, sharing insights from our ongoing work, and contributing to discussions that help shape the future of ALS research and patient care.

For more information about ENCALS 2026: https://encals-congress.com/encals2026/